Here is a conflict that has been named in print, repeatedly, and never resolved.
Medicated antifungal shampoo is dosed by frequency. Two or three times a week, with contact time, is the standard instruction.
Tightly coiled hair is mechanically damaged by the wetting, detangling and manipulation cycle, and wash frequency in Black women is measurably lower — a case-control study of hair care practices and measured hair biology found the washing frequency difference significant at p below 0.001, alongside a difference in number of broken hairs at the same p value. Both halves of the conflict, documented in one study.
So the patient is asked to choose between their scalp and their hair. And the advice given almost always treats that as a compliance problem.
The trial that answers it
In 2004, a randomized, parallel-group, double-blind, vehicle-controlled study did exactly the experiment: ciclopirox 1 percent shampoo at once, twice and three times weekly, against vehicle, in 183 patients over four weeks.
Therapeutic index, from global change in seborrheic dermatitis score:
Vehicle, 1.25. Once weekly, 3.30. Twice weekly, 3.50. Three times weekly, 3.56.
Going from nothing to once a week buys 2.05 points. Going from once to three times a week buys another 0.26.
Roughly 89 percent of the available benefit arrives with the first medicated wash of the week. The frequency-response curve is steeply front-loaded and then almost flat.
Which means a patient who can wash once a week can be told, on the basis of a double-blind vehicle-controlled trial, that they are getting most of what is on offer. That is a different conversation from the one that usually happens.
The honest limits, because they matter. A hundred and eighty-three patients across four arms is modest and the trial was almost certainly not powered to demonstrate that once-weekly is non-inferior to three-times — “no significant difference between frequencies” is not what it reported, and an absence of demonstrated difference is not equivalence. It ran four weeks, and seborrheic dermatitis is a relapsing disease where maintenance may behave differently from induction. It tested ciclopirox, not ketoconazole or zinc pyrithione. It was published in a journal supplement with a study group named after the brand, which is to say it was industry-sponsored. And the race and hair type of the participants are not reported — it is a German-led study and almost certainly not a textured-hair population.
All five caveats hold. It remains the only trial anybody has run on the variable at issue, and its direction is unambiguous.
Medicated antifungal shampoo must be used two to three times a week to work.
- Source
- Abeck D; Loprox Shampoo Dosing Study Group, "Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis," Int J Dermatol 2004;43 Suppl 1:13-16
- Participants
- 183 patients across four arms — vehicle, once, twice and three times weekly — over 4 weeks
- Measured
- Race and hair type not reported. German-led study; almost certainly not a textured-hair population.
- Not measured
- Any antifungal shampoo trial conducted in, or reporting results for, a textured-hair or predominantly Black population. None located.
Therapeutic index: vehicle 1.25, once weekly 3.30, twice 3.50, three times 3.56. The first wash per week delivers about 89% of the available gain. Industry-sponsored, four weeks, not powered for non-inferiority.
The size of the effect, from the largest trial
The largest vehicle-controlled trial of scalp seborrheic dermatitis ran 499 US patients on ciclopirox 1 percent or vehicle, twice weekly, for four weeks.
Effective treatment — defined as near-clear on disease status, scaling and erythema — was reached by 26.0 percent on the drug and 12.9 percent on vehicle. Odds ratio 2.383. Absolute difference 13.1 percentage points. Number needed to treat, about 7.6.
The active drug cleared or nearly cleared just over a quarter of patients in a month. That is the honest size of the effect, from a 499-patient double-blind trial, and it is a great deal smaller than the impression left by the aisle.
Look at the vehicle arm too. Twelve point nine percent got effectively clear from washing twice a week with plain shampoo. Mechanical removal of scale and lipid does real work, and some of what gets credited to the antifungal is the wash itself.
A head-to-head study makes the point again. A hundred and eighty-nine patients randomized to a ciclopiroxolamine-plus-zinc-pyrithione shampoo, a vehicle shampoo, or 2 percent ketoconazole gel, twice weekly for 28 days. All three, including vehicle, reduced lesional score, erythema and pruritus from day seven. It took fourteen days for the two antifungals to separate from plain shampoo. And the combination shampoo was as rapid and efficient as the ketoconazole — no demonstrated superiority for the prescription product over a well-formulated over-the-counter one.
The flaking is not dryness
The standard advice and the biology point in opposite directions.
Malassezia is lipid-dependent. It cannot make its own fatty acids and must take them from its environment — that is not contested, it is why the organism needs lipid supplementation to grow in a laboratory, and it is confirmed by whole-genome analysis.
The mechanism of seborrheic dermatitis, as set out in the foundational work: Malassezia lipase cleaves sebaceous triglycerides, liberating free fatty acids. Oleic acid alone is sufficient to initiate dandruff-like desquamation in susceptible people. The flaking is not the scalp running short of lipid. It is the scalp being irritated by what happens to the lipid that is already there.
Which puts “the scalp is dry, put oil on it” in an awkward position. Oleic acid is the dominant fatty acid in olive oil, at somewhere between 55 and 83 percent, and abundant in a great many hair oils and pomades. Olive oil is a standard laboratory medium supplement for culturing Malassezia.
Now the hard limit on what I can tell you. I could not find a single clinical study testing whether applying hair oil, grease or pomade to the scalp worsens seborrheic dermatitis, raises Malassezia burden, or raises free fatty acid levels in a person. Nor could I find any evidence supporting the “dry scalp needs oil” advice in the first place. No trial. No cohort. The closest thing is a 2011 survey of African American girls that linked oiling less often than daily with seborrheic dermatitis — an association in a cross-sectional sample, not a test of what oil on the scalp does.
So: mechanistically this is the opposite of what the biology suggests, and nobody has run the study. Both halves of that sentence are true and the second one is not an escape hatch — it is the finding. A practice followed by millions of people, recommended routinely by salons and by relatives, has never been tested against the organism it plausibly feeds.
One complication the researchers raise themselves and that keeps everyone honest: the lack of correlation between Malassezia numbers and the presence and severity of dandruff has remained perplexing. It is not simply more yeast, more flaking. The metabolite and the individual’s sensitivity to it are what matter. And the largest trial’s own framing calls the Malassezia connection controversial.
Disclosure worth carrying: the three-factor model papers came from Procter & Gamble-affiliated researchers, and P&G sells zinc pyrithione. The oleic acid work is genuinely foundational. The closing endorsement of pyrithione zinc in those papers is not disinterested.
What it looks like on skin that does not go red
The textbook cue for seborrheic dermatitis is erythema with greasy yellow scale. On richly pigmented skin that is the cue that fails.
The skin-of-color clinical literature describes scaly hypopigmented macules and patches in the typical areas, and arcuate or petal-like patches — petaloid seborrheic dermatitis. Postinflammatory pigment alteration is itself a feature. And children of color often do not get the classic cradle cap appearance at all, presenting instead with flaking and hypopigmentation in the folds.
Hypopigmented rather than red. Petals rather than plaques. It is the same erythema-visibility problem that makes a patch test reading subjective on deeply pigmented skin, turning up in yet another disease, alongside eczema severity scoring and rosacea diagnosis.
The differential overlaps with atopic dermatitis, psoriasis and rosacea — all conditions that are themselves harder to read without visible redness.
And there is no population-based prevalence figure for scalp seborrheic dermatitis or scalp psoriasis stratified by race in the United States. The frequently cited comparison — seborrheic dermatitis in the top five diagnoses for Black patients, psoriasis in the top five for white patients — comes from a single-center review of diagnosis codes at one Skin of Color Center in New York over one year, 2004 to 2005. It measures what walked through that door, at a clinic that attracts pigmentary and hair complaints by referral. It cannot tell you what is more common in a population, and it is twenty years old.
The gap underneath all of it
Every efficacy figure in this piece — the 26 percent, the 12.9 percent vehicle, the 89 percent of benefit in the first wash, the ketoconazole equivalence — comes from a trial whose participants’ hair type was not recorded and, given the study locations, was very unlikely to be predominantly textured.
There is no trial of any antifungal shampoo in a textured-hair population. None.
The field named the wash-frequency problem in print in 2019 — a modified treatment approach is needed which takes into account differences in hair texture and hair washing frequency — restated it in 2025, and has produced no tested regimen. No leave-on formulation study, no scalp-targeted applicator trial, no off-wash-day protocol, no validated reduced-frequency schedule. And the 2004 dosing trial that would substantially answer the question goes uncited in that conversation.
Nor is there any published study of which topical vehicle people with different hair types will actually use — foam, solution, oil, shampoo, ointment — or of adherence by hair type, for seborrheic dermatitis or for psoriasis. The literature asserts that vehicle and hair-care compatibility matter, repeatedly, and has never measured it.
Two things are worth knowing about that gap. The first is that it is not a recruitment problem: a psoriasis trial designed around diverse enrollment filled roughly seven times faster than its own historical baseline. The second is that the strongest published result for severe scalp psoriasis in textured hair came from an injection, which routes around the topical-delivery question rather than answering it.
Three things that follow from the dosing trial
If washing three times a week is not compatible with your hair, once a week with a medicated shampoo and real contact time is defensible, and there is a randomized trial behind that rather than a shrug. Say so at the appointment rather than nodding and doing it your way.
Do not assume the prescription is stronger. In the one head-to-head available, a ciclopirox and zinc pyrithione shampoo matched 2 percent ketoconazole.
And if you oil a flaking scalp because it reads as dry, know that the biology says the flaking is not dryness and that the oil most likely to be reached for is the one the organism grows best on. That is a mechanistic argument, not a demonstrated harm. It is also the only argument anybody has, because the study has not been done.
Evidence check: Moderate
Evidence level: one double-blind dosing trial answering the question directly, in a population whose hair type was never recorded. No antifungal shampoo trial has ever been run in textured hair.
Who was measured: the cohort plate above is on the dosing trial — 183 people, and not one line in it recording whose hair was being washed.
Sources reviewed September 13, 2026: Abeck D; Loprox Shampoo Dosing Study Group, “Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage,” Int J Dermatol 2004;43 Suppl 1:13-16, PMID 15271195. Lebwohl M, Plott T, Int J Dermatol 2004;43 Suppl 1:17-20, PMID 15271196. Lorette G, Ermosilla V, Eur J Dermatol 2006;16(5):558-64, PMID 17101479. Lewallen R, Francis S, Fisher B, et al., “Hair care practices and structural evaluation of scalp and hair shaft parameters in African American and Caucasian women,” J Cosmet Dermatol 2015;14(3):216-23, PMID 26300276. Dawson TL Jr, J Investig Dermatol Symp Proc 2007;12(2):15-19, PMID 18004291. DeAngelis YM, Gemmer CM, Kaczvinsky JR, Kenneally DC, Schwartz JR, Dawson TL Jr, J Investig Dermatol Symp Proc 2005;10(3):295-7, PMID 16382685. Elgash M, Dlova N, Ogunleye T, Taylor SC, “Seborrheic Dermatitis in Skin of Color: Clinical Considerations,” J Drugs Dermatol 2019;18(1):24-27, PMID 30681789. Turchin I, Albrecht L, Hanna S, et al., J Cutan Med Surg 2025;29(4_suppl):16S-23S, PMID 40965095. Alexis AF, Sergay AB, Taylor SC, Cutis 2007;80(5):387-94, PMID 18189024.
This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.